20_08_OP_OPVirtual_SolutionPageHeader2


Welcome to OP-Virtual – An online interactive forum to discuss the most important topics and trends impacting drug development and manufacturing outsourcing, and working with CDMOs.

Throughout the year, our Chief Editor, Louis Garguilo, brings together industry experts to discuss how sponsor companies can tackle some of today's biggest challenges in managing your CDMOs. Our audience gets to ask and have answered their questions during the presentation. Each OP-Virtual session is archived, and can be accessed at any time by registered site users.

A NEW DECADE OF OUTSOURCING: WHAT CAN WE EXPECT?

Will the "Twenty-Twenties" be as exciting as they sound for our industry? For certain, nobody saw a coronavirus outbreak put outsourcing in such a public light.

Outsourced Pharma hosted a live, virtual discussion in June 2020 focusing on four key areas: continuous manufacturing; cell and gene therapy influences; new sponsor-CDMO service models; and "Supply Chain 4.0."

MANAGING YOUR CDMOS - ADVICE FROM PROFESSIONALS WHO HAVE BEEN ON BOTH SIDES OF OUTSOURCING

At our second OP-Virtual, Outsourced Pharma Chief Editor Louis Garguilo invited professionals who have had careers at both CDMOs and biotechs to give us advice, and some best practices, regarding what they’ve learned having been on both sides of the outsourcing equation. Here are excerpts from the opening comments of our speakers.

PODCASTS WITH CHIEF EDITOR LOUIS GARGUILO

Louis_Photo_2019

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.